Investors
Nuron has raised $157 million to date through private and institutional investors.
Nuron Biotech
Nuron Biotech is developing novel biologics and vaccines for the prevention and treatment of neurodegenerative and infectious diseases. Our team of industry veterans is advancing products that meet unmet medical needs for patients around the globe. Our lead drug candidate, RELONSIV™ (interferon beta-1b) is a new chemical entity currently in Phase 3 for patients with multiple sclerosis. Nuron’s vaccine brands include Meningitec™ and HibTITER®.
